Lacipil (Lacidipine)

Lacidipine works by selectively inhibiting L‑type calcium channels in the smooth muscle of arteries. This blocks calcium entry, causing the vessels to relax and widen (vasodilation), which decreases peripheral resistance and leads to a reduction in systemic blood pressure.

The appropriate dose of Lacipil is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be required for specific populations, such as the elderly or those with liver impairment.

Safety of lacidipine in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and to discontinue breastfeeding while on therapy unless a healthcare professional advises otherwise.

To request Lacipil, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacipil belongs to the dihydropyridine calcium‑channel blocker class, offering potent arterial vasodilation with minimal direct cardiac effects. Compared with ACE inhibitors or beta‑blockers, it may be preferred when a strong vasodilatory response is needed, but combination therapy is common to achieve optimal blood‑pressure control.

Lacipil tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme heat.

Lacipil is taken orally, usually once daily with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a prescriber.

The most serious adverse events linked to Lacipil include severe hypotension, which can cause fainting, and rare cases of angioedema that may affect the airway. Prompt medical attention is required if symptoms such as sudden swelling of the face, lips, tongue or difficulty breathing occur.

Lacipil should be avoided in patients with known hypersensitivity to lacidipine or any component of the formulation, in those taking strong CYP3A4 inhibitors, and in individuals with severe hepatic impairment unless a specialist advises otherwise. Caution is also advised for patients with a history of angioedema.